Optically Pumped Magnetometer Patents

Optically pumped magnetometer patents cover sensor/physics innovations; miniaturization/array innovations; operating-condition/shielding innovations; and application innovations — with IP held by quantum-sensing companies, medical-device companies, and research organizations. WHY OPTICALLY PUMPED MAGNETOMETERS: an OPTICALLY PUMPED MAGNETOMETER (OPM) measures extraordinarily TINY magnetic fields using a small glass cell of alkali-metal vapor (RUBIDIUM or cesium): a LASER 'OPTICALLY PUMPS' the atoms, aligning their spins into a well-defined state; an external magnetic field causes those atomic spins to PRECESS/tilt by an amount proportional to the field, and the light passing through (or emitted by) the atoms reads out that tilt — giving sensitivity down to the FEMTOTESLA range (trillionths of the Earth's field); the transformative feature is that OPMs achieve this at or near ROOM TEMPERATURE with NO CRYOGENIC cooling — unlike the SQUID (superconducting) sensors that historically dominated ultra-sensitive magnetometry but require bulky liquid-helium cryostats; the KILLER APPLICATION is WEARABLE MEG (magnetoencephalography) — measuring the faint magnetic fields produced by neural activity in the BRAIN using small OPM sensors mounted in a lightweight, FLEXIBLE, WEARABLE helmet that the subject can move in, instead of sitting rigidly inside a fixed, cryogenically-cooled SQUID array — enabling brain imaging in children, during movement, and at lower cost; the brutal CHALLENGES: the SENSOR/PHYSICS (the alkali VAPOR CELL, the LASER pumping/probing, and the high-sensitivity operating regime (notably SERF — spin-exchange-relaxation-free — for femtotesla sensitivity) — the HEART), the MINIATURIZATION/ARRAY (shrinking the sensor into small, low-power modules that TILE into dense wearable arrays over the head), the OPERATING-CONDITION/SHIELDING (the most sensitive OPM mode (SERF) only works in a near-ZERO magnetic field, so magnetic SHIELDING and active field-nulling are central, as is operating while the wearer moves), and the APPLICATION (MEG, magnetocardiography, non-destructive evaluation, and navigation). MAJOR PLAYERS: QUSPIN (the leading OPM sensor maker), CERCA MAGNETICS (wearable MEG systems), FIELDLINE, plus quantum-sensing companies, NIST, and academia. Sensor/physics, miniaturization/array, operating-condition/shielding, and application are the core OPM patent domains. (Note: SENSORS (apparatus), PHYSICS PACKAGES (apparatus), and METHODS are §101-RESILIENT — so claim sensors, arrays, shielding/operation methods, and applications.)

Sensor/physics innovations; miniaturization/array innovations; SERF-magnetometer innovations; and vapor-cell innovations represent core OPM patent domains — and the sensor/physics (the heart) and the miniaturization/array (the form) are the foundational, high-value, §101-resilient capabilities. SENSOR / PHYSICS PATENTS: the HEART — the VAPOR CELL (the small alkali-vapor cell — fabrication, atom density/heating, wall coatings, and buffer gas), the LASER PUMPING/PROBING (the laser(s) that pump and probe the atoms — wavelength, modulation, and detection scheme), the SENSITIVITY REGIME (operating in the SERF (spin-exchange-relaxation-free) regime for the highest, femtotesla sensitivity, or other modes for different field ranges), and NOISE REDUCTION (suppressing noise to reach the sensitivity that makes MEG possible); sensor methods are core, high-value, DISTINCTIVE IP, §101-resilient (the VAPOR CELL, LASER pump/probe scheme, and the SERF/sensitivity regime are the central, most contested, defensible IP, since the physics package and its sensitivity are the heart — they determine whether the sensor can see brain-scale fields). MINIATURIZATION / ARRAY PATENTS: the FORM — SENSOR MINIATURIZATION (shrinking the cell, optics, and electronics into a small, low-power module that mounts on the scalp), DENSE ARRAYS (tiling many OPM sensors into a high-channel-count array over the whole head — and managing CROSS-TALK and the fields the sensors themselves produce), and WEARABLE INTEGRATION (mounting sensors in a flexible, comfortable, movable helmet); miniaturization methods are core, high-value, DISTINCTIVE IP, §101-resilient (sensor MINIATURIZATION and dense, low-cross-talk ARRAYS are core, contested, defensible IP, since wearable MEG needs many small sensors close to the head — the array is exactly what differentiates OPM-MEG from a single sensor). SERF-MAGNETOMETER PATENTS: spin-exchange-relaxation-free OPMs for femtotesla sensitivity; SERF-magnetometer methods are high-value IP, §101-resilient (SERF gives the sensitivity MEG needs). VAPOR-CELL PATENTS: alkali vapor cells for OPMs (fabrication/coatings); vapor-cell methods are high-value IP, §101-resilient (the vapor cell is the sensing element). Sensor/physics, miniaturization/array, SERF-magnetometer, and vapor-cell are the highest-value core IP because the physics package's sensitivity and the wearable array are exactly what make OPM brain imaging possible.

Operating-condition/shielding innovations; application innovations; wearable-MEG innovations; and magnetocardiography innovations represent additional OPM patent domains — and the operating-condition/shielding (the constraint) and the application (the use) turn the sensor into a working system. OPERATING-CONDITION / SHIELDING PATENTS: the CONSTRAINT — MAGNETIC SHIELDING (the most sensitive SERF OPMs need a near-ZERO ambient field, so magnetically SHIELDED rooms/enclosures and lightweight shielding are central — and a major cost/footprint driver to reduce), ACTIVE FIELD NULLING (coils and control that cancel residual and changing fields (including the Earth's) so the wearer can MOVE — critical for practical wearable MEG), DYNAMIC RANGE (extending OPM operation to larger/changing fields, e.g., for less-shielded or moving use), and MOVEMENT COMPENSATION (allowing head movement during a scan); operating methods are core, high-value, DISTINCTIVE IP, §101-resilient (MAGNETIC SHIELDING, ACTIVE FIELD NULLING, and movement compensation are core, contested, defensible IP, since OPM's near-zero-field requirement and the need to let subjects MOVE are exactly the practical barriers to real-world wearable MEG — solving them is decisive). APPLICATION PATENTS: the USE — WEARABLE MEG (the flagship — brain imaging with on-scalp OPM arrays, enabling lifespan/pediatric/naturalistic neuroscience and clinical use (epilepsy, etc.)), MAGNETOCARDIOGRAPHY (measuring the heart's magnetic field for cardiac diagnostics), NON-DESTRUCTIVE EVALUATION/SECURITY (detecting magnetic signatures), and NAVIGATION/MAGNETIC SENSING (precise magnetometry for navigation/geophysics); application methods are core, high-value, DISTINCTIVE IP, §101-resilient when tied to the device (WEARABLE MEG and MAGNETOCARDIOGRAPHY are core value, since brain and heart magnetic imaging without cryogenics are exactly where OPMs transform the field). WEARABLE-MEG PATENTS: on-scalp wearable OPM magnetoencephalography systems; wearable-MEG methods are high-value IP, §101-resilient when tied to the system (wearable MEG is the killer application). MAGNETOCARDIOGRAPHY PATENTS: OPM-based cardiac magnetic imaging; magnetocardiography methods are high-value IP, §101-resilient when tied to the device. Operating-condition/shielding, application, wearable-MEG, and magnetocardiography are the highest-value IP because solving the near-zero-field/movement constraint and the brain/heart imaging applications turn the sensor into a transformative system.

Optically pumped magnetometer startup IP strategy must navigate the sensor-physics-package-and-method-are-§101-resilient (OPM IP is SENSOR (apparatus), PHYSICS PACKAGE (apparatus), and METHOD IP — strongly §101-RESILIENT — so sensor, array, shielding, and application claims are strong), the no-cryogenics-room-temperature-operation-is-the-strategic-advantage-over-SQUIDs (the transformative advantage over SQUID magnetometers is that OPMs need NO CRYOGENIC cooling and run at/near room temperature — enabling small, wearable, lower-cost sensors — so this cryogen-free, wearable advantage is the core strategic value to build IP around), the sensitivity-SERF-regime-is-the-heart-that-enables-MEG (reaching FEMTOTESLA sensitivity (typically via the SERF regime) is the heart that lets OPMs see brain-scale fields — so sensor/physics and sensitivity IP is the central, foundational asset), the wearable-array-not-a-single-sensor-is-the-product (wearable MEG needs MANY small sensors tiled densely over the head — so dense, low-cross-talk ARRAY and miniaturization IP (not a single sensor) is what makes the product, and a key differentiator), the shielding-and-field-nulling-are-the-central-practical-make-or-break (SERF OPMs need a near-ZERO field and must work while the wearer MOVES — so magnetic SHIELDING, ACTIVE FIELD NULLING, and movement compensation are the central practical make-or-break (and a major cost/footprint driver), and reducing the shielding burden is high-value IP), the wearable-MEG-is-the-killer-application-with-a-clinical-and-research-market (the killer app is WEARABLE MEG for neuroscience and clinical brain imaging (pediatric, naturalistic, epilepsy) — a real, growing market where OPMs beat cryogenic SQUID-MEG — so target it, with magnetocardiography and sensing as adjacencies), the sensor-vs-system-vs-clinical-business-models (a startup can sell OPM SENSORS/modules (like QuSpin), full wearable MEG SYSTEMS (like Cerca), or operate clinical/research SERVICES — the model is a key choice, and a great sensor is a 'picks and shovels' asset for the whole field), the regulatory-path-matters-for-clinical-use (clinical MEG/MCG use needs medical-device regulatory clearance — a gating factor beyond IP for the clinical market), the incumbent-and-FTO (QuSpin (dominant sensor maker), Cerca Magnetics, FieldLine, NIST, and academia hold significant OPM IP — so a startup needs a genuinely novel sensor/array/shielding/application edge and careful FTO around the leading sensor patents), the demonstrated-sensitivity-array-density-shielding-and-movement-decide (OPM systems are proven by demonstrated SENSITIVITY (fT), ARRAY channel count, SHIELDING/footprint, and the ability to operate during MOVEMENT — so demonstrated, system-level performance is decisive, more than patents alone), and a landscape where sensor, array, shielding, and application are the durable assets; understand that cryogen-free sensitivity is the strategic advantage and shielding/field-nulling is the central practical make-or-break, so the durable startup IP is in sensitive physics packages, dense wearable arrays, shielding/field-nulling, and MEG/cardiac applications — with a more sensitive small sensor or reduced-shielding/movement-tolerant operation often the real moat, and that §101-resilient sensor/method IP, demonstrated sensitivity/array/shielding/movement, regulatory clearance, and FTO matter as much as patents; identify whitespace in sensors, arrays, shielding/nulling, and applications. OPTICALLY PUMPED MAGNETOMETER STARTUP IP STRATEGY: SENSOR/PHYSICS, MINIATURIZATION/ARRAY, OPERATING-CONDITION/SHIELDING, AND APPLICATION ARE THE IP: patent sensors, arrays, shielding, and applications — apparatus + method claims (§101-resilient); SENSOR-PHYSICS-PACKAGE-AND-METHOD-ARE-§101-RESILIENT: SENSOR + PHYSICS PACKAGE (apparatus) + METHOD IP — strongly §101-RESILIENT; NO-CRYOGENICS-ROOM-TEMPERATURE-OPERATION-IS-THE-STRATEGIC-ADVANTAGE-OVER-SQUIDS: OPMs need NO CRYOGENIC cooling (vs SQUIDs) — small/wearable/lower-cost — the core strategic value; SENSITIVITY-SERF-REGIME-IS-THE-HEART-THAT-ENABLES-MEG: FEMTOTESLA sensitivity (SERF) lets OPMs see brain fields — sensor/physics + sensitivity IP the central foundational asset; WEARABLE-ARRAY-NOT-A-SINGLE-SENSOR-IS-THE-PRODUCT: wearable MEG needs MANY small sensors tiled densely — dense low-cross-talk ARRAY + miniaturization IP makes the product; SHIELDING-AND-FIELD-NULLING-ARE-THE-CENTRAL-PRACTICAL-MAKE-OR-BREAK: SERF needs near-ZERO field + must work while the wearer MOVES — magnetic SHIELDING/ACTIVE FIELD NULLING/movement compensation the central practical make-or-break (+ cost/footprint driver); WEARABLE-MEG-IS-THE-KILLER-APPLICATION-WITH-A-CLINICAL-AND-RESEARCH-MARKET: WEARABLE MEG (pediatric/naturalistic/epilepsy) the killer app beating cryogenic SQUID-MEG — target it (+ magnetocardiography/sensing adjacencies); SENSOR-VS-SYSTEM-VS-CLINICAL-BUSINESS-MODELS: sell SENSORS (QuSpin, picks-and-shovels), wearable MEG SYSTEMS (Cerca), or clinical SERVICES — a key choice; REGULATORY-PATH-MATTERS-FOR-CLINICAL-USE: clinical MEG/MCG needs medical-device clearance — a gating factor; INCUMBENT-AND-FTO: QuSpin (dominant)/Cerca Magnetics/FieldLine/NIST + academia — need a novel sensor/array/shielding/application edge + careful FTO; DEMONSTRATED-SENSITIVITY-ARRAY-DENSITY-SHIELDING-AND-MOVEMENT-DECIDE: proven by SENSITIVITY-fT/ARRAY channel count/SHIELDING-footprint/MOVEMENT operation — demonstrated system performance decisive; WHEN TO PATENT: NOVEL SENSOR/ARRAY/SHIELDING/APPLICATION WITH DATA: file once it shows data (sensitivity + array + shielding/nulling + application) — apparatus + method claims; demonstrated sensitivity, array density, shielding, and movement tolerance are the critical OPM IP metrics; KEY FTO CHECKLIST: QuSpin/Cerca Magnetics/FieldLine/NIST + academia; sensor/physics (alkali VAPOR CELL/LASER pump-probe/SERF sensitivity regime/noise — §101-resilient, the heart); miniaturization/array (sensor MINIATURIZATION/dense ARRAYS-cross-talk/wearable integration — §101-resilient, the form); SERF-magnetometer (the femtotesla sensitivity); vapor-cell (the sensing element); operating-condition/shielding (MAGNETIC SHIELDING/ACTIVE FIELD NULLING/dynamic range/movement compensation — §101-resilient, the constraint); application (WEARABLE MEG-brain/MAGNETOCARDIOGRAPHY-heart/NDE-security/navigation — tie to device); wearable-MEG (the killer application); magnetocardiography; sensor + physics package + method the §101-resilient strength; no-cryogenics room-temperature operation the strategic advantage over SQUIDs; sensitivity SERF regime the heart that enables MEG; wearable array not a single sensor the product; shielding + field nulling the central practical make-or-break; wearable MEG the killer application with a clinical + research market; sensor vs system vs clinical business models; regulatory path matters for clinical use; incumbent (QuSpin) + FTO; demonstrated sensitivity + array-density + shielding + movement decide.